Cargando…
Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation
Imprime PGG (Imprime), an intravenously-administered, soluble β-glucan, has shown compelling efficacy in multiple phase 2 clinical trials with tumor targeting or anti-angiogenic antibodies. Mechanistically, Imprime acts as pathogen-associated molecular pattern (PAMP) directly activating innate immun...
Autores principales: | Chan, Anissa S. H., Jonas, Adria Bykowski, Qiu, Xiaohong, Ottoson, Nadine R., Walsh, Richard M., Gorden, Keith B, Harrison, Ben, Maimonis, Peter J., Leonardo, Steven M., Ertelt, Kathleen E., Danielson, Michael E., Michel, Kyle S., Nelson, Mariana, Graff, Jeremy R., Patchen, Myra L., Bose, Nandita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094785/ https://www.ncbi.nlm.nih.gov/pubmed/27812183 http://dx.doi.org/10.1371/journal.pone.0165909 |
Ejemplares similares
-
Imprime PGG, a yeast β-glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype
por: Chan, Anissa SH, et al.
Publicado: (2014) -
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
por: Chan, Anissa S. H., et al.
Publicado: (2022) -
Imprime PGG, an innate immunomodulator for cancer immunotherapy has the potential to modulate macrophages in the tumor and the spleen to an anti-tumor M1-like phenotype
por: Fraser, Kathryn, et al.
Publicado: (2015) -
Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent
por: Bose, Nandita, et al.
Publicado: (2013) -
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
por: Thomas, M., et al.
Publicado: (2017)